Seliciclib Recruiting Phase 2 Trials for Cushing's Disease Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03774446Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease